George Papaxoinis
Overview
Explore the profile of George Papaxoinis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fountzilas E, Papadopoulos T, Papadopoulou E, Gouedard C, Kourea H, Constantoulakis P, et al.
Diagnostics (Basel)
. 2024 Jun;
14(11).
PMID: 38893603
Determination of microsatellite instability (MSI)/mismatch repair (MMR) status in cancer has several clinical implications. Our aim was to integrate MSI/MMR status from patients tested in Greece to assess the prevalence...
2.
Moutafi M, Koliou G, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, et al.
Cancer Res Commun
. 2023 Aug;
3(8):1514-1523.
PMID: 37575280
Purpose: We conducted a phase II randomized noncomparative window of opportunity (WOO) trial to evaluate the inhibition of cellular proliferation and the modulation of immune microenvironment after treatment with olaparib...
3.
Kole C, Charalampakis N, Sakellariou S, Papaxoinis G, Apostolou K, Machairas N, et al.
J Pers Med
. 2022 Dec;
12(12).
PMID: 36556253
Gastric cancer is ranked fifth among the most commonly diagnosed cancers, and is the fourth leading cause of cancer-related deaths worldwide. The majority of gastric cancers are sporadic, while only...
4.
Spurgeon L, Jones J, Lewis A, Rammohan K, Shaheen F, Weaver J, et al.
J Neuroendocrinol
. 2022 Jul;
34(7):e13180.
PMID: 35894811
Typical and atypical bronchial carcinoid account for around 2% of all neuroendocrine neoplasms of pulmonary origin. Fewer than 5% of patients with these cancers are thought to develop brain metastases,...
5.
Kamposioras K, Papaxoinis G, Dawood M, Appleyard J, Collinson F, Lamarca A, et al.
Acta Oncol
. 2022 Apr;
61(5):583-590.
PMID: 35392758
Background: Identifying pretreatment blood markers that distinguish prognostic groups of patients with advanced pancreatic ductal adenocarcinoma (PDAC) under first-line FOLFIRINOX chemotherapy has the potential to improve management of this condition....
6.
Mammas C, Mamma A, Papaxoinis G, Georgiou I
Stud Health Technol Inform
. 2022 Jan;
289:309-312.
PMID: 35062154
Aim: Feasibility-reliability control of Telemedicine Systems (TS) integrated with Multimedia Systems (MS) and Artificial intelligence (AI) for remote e-Multidisciplinary Oncology Conference in Breast Cancer. Material And Methods: Forty (n1=40) patients...
7.
Wells K, Lamrca A, Papaxoinis G, Wallace A, Quinn A, Summers Y, et al.
J Clin Pathol
. 2022 Jan;
76(7):463-466.
PMID: 35039450
Aim: Recent study has revealed frequent GTF2I mutation in thymomas, with the frequency being highest in types A and AB, followed by B1, B2, B3 and thymic carcinoma. This has...
8.
Kole C, Charalampakis N, Tsakatikas S, Kouris N, Papaxoinis G, Karamouzis M, et al.
Immunotherapy
. 2021 Nov;
14(1):41-64.
PMID: 34784774
Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority of patients with gastric cancer...
9.
Gouveris P, Zouki D, Sarris E, Kolilekas L, Tryfonopoulos D, Papaxoinis G, et al.
Case Rep Oncol
. 2021 Jul;
14(2):1059-1065.
PMID: 34326742
Sarcoidosis and sarcoid-like reactions have been associated with many solid tumors including malignant melanoma. There are reports of melanoma patients who develop sarcoidosis without having received any antineoplastic treatment, but...
10.
Fountzilas E, Lampaki S, Koliou G, Koumarianou A, Levva S, Vagionas A, et al.
Cancer Immunol Immunother
. 2021 Jun;
71(2):327-337.
PMID: 34164709
Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical...